zuyd university of applied sciencesamici.lifescienceopenspace.pl/wp-content/uploads/...assessment of...
TRANSCRIPT
1
Zuyd University of AppliedSciences
UK
France
Germany
Limburg: a gateway to Europe
9 faculties• Bèta Sciences and Technology• Commercial and Financial Management• Health• Hotel and Facility Management• ICT• International Business and
Communication• Art• Management and Law• Social Studies and Education
48 Bachelor and Master degreeprogrammes
3 mainactivities
• Education• Research• Training
14,000 students
1,800 employees
4
Life Siences and Materials
3focus areas
Transition to a Sustainable Built Environment
Innovative Care andTechnology
3 Centresof Expertise
5
• CHILL: Chemelot Innovation andLearning Labs
• EIZT:Innovative Care andTechnology
• NEBER: New Energy, Built Environment and Renewables
6
7
Antimicrobial projects
Agenda (continued)
9. Selection of Grant Holder Institution and FSAC
10. Presentation and discussion of the AMiCI Action
11. Establishment of AMiCI Management Structure
lunch break
12. AMiCI Implementation Planning
13. Any Other Business
14. Closing
9b. The FSAC rate for the Grant Holder Institution
Financial, Scientific and Administrative Coordination
• Proposition: 15%
• To support the execution of the administrative tasks relating to managing and coordinating scientific activities
• Coordination of Action Meetings and Participation of Grant Manager at certain Action Meetings
• Reimbursements according to eligibility criteria of COST
• Preparation and delivery of reports
• Any unforeseen costs not reimbursed according to COST criteria but necessary to keep the Action running
Nosocomial infections in the media
10a. AntiMicrobial Coating Innovations to preventinfectious diseases
Socio-economic impact of failing hygiene:chances for nano
Contamination
often occurs by
transmission
from surfaces
Nanobased vs the rest
Nanotechnoloy, Science and Applications
Molling et al, Nanotechnology, Science and applications (2014)
• Shorter hospital stays
• Smaller number of re-treatment/recurrence
• Less costs related to logistics and materials related to
cleaning, chemicals, waste and equipment.
• Insurance costs as well as cost for court/lawyers
• Lower incidence of HAI and antimicrobial resistance
• A more sustainable approach
• Less cleaning costs
Better hygiene leads to reduced HAI & costs:
Antimicrobial coatings can add to:
• Effect of coatings in specific locations?
• Durability of the effect?
• New cleaning protocols?
• Compatibility with current chemicals and
procedures?
• Effect on resistant bacteria?
• New resistance mechanisms?
Need for benchmarks and information
Assessment of bacterial contamination
• Coatings judged by slow ISO-NEN protocol
(best-case, close contact needed).
• PCR can be used to rapidly (2-4 hrs)
assess presence and load of bacteria.
• New methods and equipment is needed for
Point-of-care detection of bacteria and
local intervention.
Reasons for so-far limited introduction of AMCs in healthcare
• Lack of systematic, international coördinated research on the effects of AMCs on
non-invasive materials and surfaces in healthcare
• Lack of knowledge on availability and use of different AMCs
• Insufficient information on possible adverse effects of AMCs
• Lack of standard performance assessment for AMCs in lab and field conditions or
benchmark tests
• Lack of Best Practices
10a. Main objective AMiCI
Evaluate the impact of (introducing) AntiMicrobial Coatings in
healthcare on the spread of infections and on the efficacy of
fighting Healthcare Associated Infections (HCAIs) and bacterial
resistance to current antibiotics.
AMiCI objectives / Research Coordination:
o Consult and support policy and healthcare sector regarding further actions and application of
AMC (WG3)
o Use know-how and expertise of the network to stimulate development/optimisation of
antimicrobial materials for non-invasive surfaces (WG1)
o Gather best practices and convert these into standardised methods to evaluate/compare AMC
effectiveness in lab setting, with possibilities to extrapolate to field tests (WG2)
o Gather best practices and convert these into field tests that enable evaluation of effectiveness of
the use of AMC in prevention of spread of infections in healthcare (WG2)
o Gather information on the impact of introduction of AMCs on development of multi-drug
resistance and possible development of AMR to AMCs (WG3)
o Establish approach for risk-benefit analysis for using AMCs in healthcare environments (WG3)
o Determine the effects of AMCs on the cleaning process in healthcare (WG4)
o Disseminate knowledge on AMC innovations and lab and field tests to stakeholders (WG5)
o Disseminate findings on new cleaning procedures / logistics upon introduction of AMCs into
healthcare and other sectors (WG5)
o Coordinate (inter)national research efforts to join forces in combatting AMR (WG1-2-3-4-5)
10a. Objectives Capacity Building
AMiCI objectives / Capacity Building:
o Develop and maintain a European network involving all stakeholders (producers, suppliers and
users) of AMC in healthcare and organisations involved with standards on hygiene (WG 5)
o Stimulate collaboration between industry and research institutes using available knowledge and
disclose state-of-the-art knowledge to industrial partners, leading to more effective AMC’s and
successful new market applications (WG5)
o Involvement of early-career investigators (<8 years after PhD) (WG1-2-3-4-5)
Management Committee- Chair + Vice-Chair- Scientific Representative- WG Leaders and Vice-Leaders- National Representatives
Core Group- Chair + Vice-Chair MC- WG Leaders- STSM / ECI Coordinator
WG1 WG2 WG4WG3 WG5
COST Association
Grant Holder
10b. AMiCI: Management structure
Communication CoordinatorGrants Coordinator
10b. Working Group 1
WG1 Antimicrobial materials Safe-by-Design
Reaching a conceptual understanding of the mechanisms and construction of an active and sustainable coating, to adapt current and develop new coatings to meet ECHA standards
Deliverables/Milestones - Database combining active ingredients and substrates for use of AMC in healthcare
- Exchange of unpublished AMC information between Action members on AMC development and application in healthcare
- Opinion paper on safe-by-design approaches for development and application of AMC
10b. Working Group 2
WG2 Performance assessment (lab-field-benchmark)
Development of lab and field benchmark tests to evaluate efficacy andefficiency of AMCs to reduce bacterial contamination in the environment of patients in healthcare
Deliverables/Milestones - Exchange of unpublished information on AMC lab/field tests between partners
- Benchmark test to establish efficacy and efficiency of AMCs in healthcare- Guidelines on test methods for AMC performance assessment
10b. Working Group 3
WG3 Adverse effects / Risk-benefit analysis
Focus on (eco)toxicological risks and possible introduction of AMR resulting from the use of AMC
Deliverables/Milestones - Inventory/review on current knowledge of impact of AMCs on ecosystems- Risk/benefit analysis based on inventory of available knowledge on
(eco)toxicological aspects of AMCs and possible development of AMR to AMC
- Recommendations on further development and application of AMCs in healthcare, taking into account the risk/benefit analysis
- Expert statement on further research and policy with regard to prevention of antimicrobial resistance
- Inform regulatory bodies and analytical services on risks and benefits of AMCs in healthcare
10b. Working Group 4
WG4 The new cleaning
Investigate new methods of effective cleaning, additional to the use of AMCs to ensure a safe and more hygienic future
Deliverables/Milestones - Comparison of AMC-based cleaning systems regarding safety, efficacy, sustainability and durability to the frequently used systems in healthcare
- Guidelines on new cleaning procedures, in compliance with and additional to the use of AMCs, for cleaning industries in healthcare
10b. Working Group 5
WG5 Communication and dissemination
Communicate and disseminate knowledge gathered and developed by AMICI members
Deliverables/Milestones - Project website - Database of experts in the field- Organisation of meetings and events- Participation in meetings and conferences of other networks and
stakeholders- Involvement of Framework Program policy makers to mid-term and final
Action conferences- Expansion of AMiCI network with key stakeholders including producers,
suppliers and (potential) users of AMC in healthcare and organisations involved with hygiene standards
- Exchange of ECI’s between institutes of different countries and between knowledge institutes and industry
10b. Implementation of Scientific Committee recommendations and COST policies
‘The proposed Action must develop and implement clear plans to ensure increased participation of Early Career Investigators and female researchers, and to increase the participation of academic partners.’
• After publication of MoU a lot of academic partners joint the Action
• Installation of STSM manager with specific target to involve ECI
• WG Leaders need to include ECI as WG member (proposal: >20% of each WG)
April 2016:
• 24 Countries involved, of which 11 Inclusiveness Target Countries
• 68 MC Members/substitutes, xx Early Career Investigators
• 39 males, 27 females
• 59 % academic partners (excl. research institutes, 74% incl. research institutes)
11a. Establishment of AMiCI Management Structure
ProposalPosition Candidate
Vice-Chair Minna Keinänen-Toivola (FI)
WG1 - Antimicrobial materials Safe by Design Leader Hulya Olmez (TR)
Vice-Leader Luis Melo (PT)
WG2 - Performance assessment Leader Peter Askew (UK)
Vice-Leader Birgit Teunissen (NL)
WG3 - Adverse effects / risk-benefit analysis Leader Anne Kahru (Estonia)
Vice-Leader Merja Ahonen (FI)
WG4 - The new cleaning Leader Martina Modic (Slovenia)?
Vice-Leader Ireland, Germany or Greece?
WG5 - Communication and dissemination Leader Kazimierz Murzyn (PL)
Vice-Leader Theofilos Papadopoulos (GR)
STSM / ECI Manager Isabel Gouveia (PT)
11b. Other Management (support) roles
• Communication Coordinator: Ellen de Waal – Scientific Affairs
(NL)
• Grant Writing Coordination: Raymunde Neven – Zuyd
University of Applied Science (NL)
11b. Mandates to be discussed
• Approval of STSM applications by STSM coordinator and Chair
• In case of underspending in 1 activity, the core group may
decide to use unspent funds for other COST activities
• In case of non-response, the GH can cancel non answered
invitations to meetings after 14 days of sending the invitation
12. Action implementation planning
Discussion in separate WGs:
• Deliverables
• Tasks and indicators to achieve WG objectives and deliverables
• WG members: who/which expertise is needed additionally to
achieve WG objectives and deliverables
• Objectives,tasks and deliverables during the 1st grant period
(May 1, 2016 – April 30, 2017)
See hand-out
12. Action implementation planning
COST networkingtools
Year 1 Year 2 Year 3 Year 4
MC meeting X X X X X
Core groupmeeting
X X X X X X X X
WG meeting X X X X
STSM X X X X X X X X X X X X X X
Training school X X X
Action Conference X X
Dissemination,publications
X X X X X X X X X X X X X X X X
12b. Action implementation planning: 1st Grant Period – 1 May 2016-30 April 2017
A - COST networking tools Year 1 Budget€
MC meeting (X) X
90,000Core group meeting X X
WG meeting X
Action Conference
STSM X X 7,000
Training school
Dissemination, publications X X X X 7,000
OERSA X X X X 1,200
B – Total Science expenditure 105,200
C – FSAC (15% of B) 15,780
D – Total Expenditure (B+C) 120,980
13. Any other business
• Virtual core group meetings and WG meetings via HILL
(supported by SAMK - Finland) or similar tools
• Core group meeting in Porto, before Biofilm7 conference
(26-28 June 2016)
• Dissemination meeting, launch our AMiCI COST Action @ICAR
2016 in Torremolinos-Malaga (29 June-1 July 2016)
• Next MC meeting in Maastricht, The Netherlands?
14. Closing
Thank you for your attention&let’s make AMiCI a success!